One case of iodine-125 therapy – A new minimally invasive treatment of intrahepatic cholangiocarcinoma-Reference-Cited by-同舟云学术

One case of iodine-125 therapy – A new minimally invasive treatment of intrahepatic cholangiocarcinoma

Published:2022-01-01 Issue:1 Volume:17 Page:1309-1314
ISSN:2391-5412
Container-title:Open Life Sciences
language:en
Short-container-title:

Author:

Chen Xinju¹,Chen Xiaoqi¹,Zhang Chuanlei¹,Wang Xinting¹,Yuan Changwei¹,Yang He¹,Yang Lixia¹

Affiliation:

1. Department of Purchasing Center, The First Affiliated Hospital of Henan University of Chinese Medicine , No. 19, Renmin Road , Zhengzhou , Henan, 450000 , P.R. China

Abstract

Abstract Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer associated with a poor prognosis. ICC accounts for about 10% of primary liver malignancies but with increasing incidence in recent years. Recently, some studies suggested that minimally interventional therapy can be used in the treatment of ICC. However, there are few references on interventional therapy for the clinical treatment of ICC. Herein we reported a case of a 48-year-old man who suffered from ICC. The patient was diagnosed with ICC by computerized tomography scan and pathological biopsy. The patient was completely cured by minimally interventional therapy with iodine-125 seed implantation. These results provide an important reference for the treatment option of ICC.

Publisher

Walter de Gruyter GmbH

Subject

General Agricultural and Biological Sciences,General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Neuroscience

Link

https://www.degruyter.com/document/doi/10.1515/biol-2022-0473/pdf

Reference20 articles.

1. Sirica AE, Strazzabosco M, Cadamuro M. Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression. Adv Cancer Res. 2021;149:321–87.

2. Mandrekar P, Cardinale V. Periostin and mesothelin: Potential predictors of malignant progression in intrahepatic cholangiocarcinoma. Hepatol Commun. 2018;2(5):481–3.

3. Spratt B, Kozan E, Sinnott M. Analysis of uncertainty in the surgical department: Durations, requests and cancellations. Aust Health Rev. 2019;43(6):706–11.

4. Seidensticker R, Seidensticker M, Doegen K, Mohnike K, Schütte K, Stübs P, et al. Extensive use of interventional therapies improves survival in unresectable or recurrent intrahepatic cholangiocarcinoma. Gastroenterol Res Pract. 2016;2016:8732521.

5. Ierardi AM, Angileri SA, Patella F, Panella S, Lucchina N, Petre EN, et al. The role of interventional radiology in the treatment of intrahepatic cholangiocarcinoma. Med Oncol. 2017;34(1):11.